This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Q1 Earnings Beat, Sales Miss, 2018 View Intact
by Kinjel Shah
Pfizer (PFE) beat expectations for earnings but missed the same for revenues in Q1. It retained its previously issued guidance for 2018.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
by Zacks Equity Research
McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview
Amazon (AMZN) Q1 Earnings Crush Estimates, Sales Surge Y/Y
by Zacks Equity Research
Amazon's (AMZN) first-quarter results benefit from robust revenue growth in the AWS segment.
Why Pfizer (PFE) Might Surprise This Earnings Season
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
by Zacks Equity Research
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .
What's in the Offing for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.
Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
by Zacks Equity Research
With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.
Is FlexShares Quality Dividend Defensive Index Fund (QDEF) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for QDEF
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
What's in the Cards for Merck (MRK) This Earnings Season?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
by Sweta Killa
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
Will Midterms Throw Markets Helter-Skelter? 5 Top Picks
by Tirthankar Chakraborty
In the last 11 midterm election years since 1974, the S&P 500 managed to eke out gains in April, but, mostly traded flat through September only to rally once political uncertainty waned.
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
NYSE to Soon Greet The Fearless Girl Statue
by Sweta Killa
The Fearless Girl statue, a global symbol of female business prowess, is moving in front of the New York Stock Exchange by the end of this year.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.